Phase 2 N=18 Evaluation of Blood as a Submucosal Cushion During Endoscopic Polypectomy and Mucosal Resection
Large Polyps in the Gastrointestinal Tract
Primary: Duration of the Submucosal Cushion
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=15 Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma
Multiple Myeloma
Primary: Number of Patients Exhibiting a Given Overall Response as Determined by Investigator — 0; 0; 0; 0 participants
N/A N=290 MyoSure Hysteroscopic Tissue Removal System Registry Study
Uterine Fibroids · Polyps
Primary: Procedure Efficacy — 95.4 percent of pathology
Phase 4 N=80 Comparison of NovaFerrum® vs Ferrous Sulfate Treatment in Young Children With Nutritional Iron Deficiency Anemia
Iron Deficiency Anemia
Primary: Hemoglobin Concentration Over Time — 7.7; 7.9; 9.3; 10.4 g/dL — p=<0.001
Phase 2 N=27 Kuvan in People With Schizophrenia and Schizoaffective Disorder
Schizophrenia · Schizoaffective Disorder
Primary: Final Positive and Negative Symptom Scale (PANSS) — 54.4; 60.2 PANSS Total — p=.38
Phase 2 N=136 Study Evaluating HKI-272 (Neratinib) In Subjects With Advanced Breast Cancer
Breast Neoplasms · Neoplasms
Primary: 16-week Progression Free Survival — 58.2; 77.8 percentage of participants
Phase 2 N=64 Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer
Breast Cancer · Triple Negative Breast Cancer · Stage IV Breast Cancer
Primary: Objective Response Rate — 28; 38 percentage of patients
Phase 4 N=121 Glaucoma Biomarkers
Glaucoma · Healthy
Primary: Variation in Eye Pressure Between Individuals. — 11.5; 11.3; 11.0; 11.0 mmHg — p=0.0001
Phase 2 N=71 Safety and Tolerability of Antiplaque Chewing Gum in a Gingivitis Population
Plaque · Gingivitis
Primary: Safety and Tolerability of KSL-W as Measured by Soft Tissue Erythema, Ulceration and Sloughing (AEs and SAEs) — 2; 1; 4; 2 Participants
Phase 3 N=110 A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066
Parkinson's Disease
Primary: Percentage of "OFF" Time During Waking Hours — 23.98; 32.48 Percent
Phase 4 N=99 Treating Disrupted Sleep in Individuals With Inflammatory Bowel Disease
Sleep Disturbance · Fatigue · Inflammatory Bowel Disease
Primary: Change From Baseline in Multidimensional Fatigue Inventory (MFI) for Each Arm — 18.727; -1.828; 16.367 units on a scale — p=<0.005
Phase 2 N=110 Enoxaparin Metabolism in Reconstructive Surgery Patients
Venous Thromboembolism · Deep Venous Thrombosis · Pulmonary Embolus
Primary: Number of Participants With Venous Thromboembolism Events — 5; 0 Participants
Phase 2 N=160 Ganciclovir/Valganciclovir for Prevention of CMV Reactivation in Acute Injury of the Lung and Respiratory Failure
Acute Lung Injury · Acute Respiratory Distress Syndrome · Respiratory Failure
Primary: Serum IL-6 Level — -0.79; -0.79 pg/mL
N/A N=74 HOME Study: Hysteroscopic Office Myomectomy Evaluation
Uterine Fibroids · Polyps
Primary: Percent Reduction in Target Pathology Volume — 96.9; 99.9 percentage of fibriods/polyps
Phase 4 N=201 Efficacy Study of Articaine Versus Lidocaine as Supplemental Infiltration in Inflamed Molars
Irreversible Pulpitis
Primary: Anesthetic Success Rate of Supplemental Infiltration Injection — 22; 25; 23; 12 Participants — p=.901